Return
01761262_CD_1127811037

Specific Maternal Health Problems Targeted for Improvement by the Joint Commission

This article excerpts a HealthStream article by Trisha Coady, BSN, RN, Senior Vice President and General Manager of HealthStream’s Clinical Solutions, about the new perinatal care standards that have been issued by the Joint Commission.

Multiple health conditions occur during pregnancy and after delivery that put the mother and child’s lives at risk. Three of the most significant are explicitly addressed in these new Joint Commission Guidelines. Understanding them, as well as understanding the standard treatments for avoiding or addressing them, can help a reader understand just how negligent some healthcare providers have been in their precautions.

Post-Partum Hemorrhage

According to the Children’s Hospital of Philadelphia, “Postpartum hemorrhage is excessive bleeding following the birth of a baby. About 1 to 5 percent of women have postpartum hemorrhage and it is more likely with a caesarean birth. Hemorrhage most commonly occurs after the placenta is delivered. The average amount of blood loss after the birth of a single baby in vaginal delivery is about 500 ml (or about a half of a quart). The average amount of blood loss for a cesarean birth is approximately 1,000 ml (or one quart). Most postpartum hemorrhage occurs right after delivery, but it can occur later as well” (CHOP.edu, n.d.). In addition to assessing mothers for hemorrhage risk, clinicians should monitor for cumulative blood loss during delivery and have a treatment cart with supplies nearby.

Severe Hypertension

Maternal hypertension, also known as gestational hypertension, “is a form of high blood pressure in pregnancy. It occurs in about 6 percent of all pregnancies. Another type of high blood pressure is chronic hypertension--high blood pressure that is present before pregnancy begins” (CHOP.edu, n.d.). Treatment involves “measurement and assessment of BP and urine protein for all pregnant and postpartum women” (Council on Patient Safety in Women’s Health Care, 2015) and medication treatment and other escalation measures as needed.

Preeclampsia

The Mayo Clinic shares that “Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. Preeclampsia usually begins after 20 weeks of pregnancy in women whose blood pressure had been normal” (Mayo Clinic Staff, n.d.). According to the Preeclampsia Foundation, prevention and timely treatment occurs when the healthcare provider watches “for signs of instability in the mother, including very high blood pressure that’s not responding to antihypertensive drugs, signs the kidneys and/or liver are failing, and a reduced number of red blood cells or platelets. Providers also watch closely for indications of an impending seizure or signs the brain is about to stroke and may treat the patient with magnesium sulfate (an anticonvulsant specifically used for preeclampsia). Antihypertensive drugs will be used if blood pressure rises to dangerously high levels, 160/110 or higher” (Preeclampsia.org, 2018). The Joint Commission Standards establish multiple requirements for improving maternal care and outcomes. For example, they call “for maternity units to keep life-saving medications immediately accessible. Hospitals also must plan for the rapid release of blood supplies for transfusions” (Stein, 2019). Because a rapid response is often essential when dealing with complications, the standards focus strongly on making equipment and medication available for when they are needed. 

In addition, the article includes:

  • Uncovering the Serious Problems That Exist in Maternal Healthcare
  • Why is Joint Commission accreditation important?
  • How the maternal safety standards were compiled

Download this article, “New Joint Commission Guidelines Target Poor Maternal Mortality Outcomes,” to learn about the new Joint Commission safety standards for the improvement of maternal and perinatal care, and why it has taken so long for the US to understand the need for them.

HealthStream Focuses on Clinical Development

At HealthStream we spend a lot of time focused on improving outcomes by developing the clinical workforce. HealthStream’s jane™ is The World’s First Digital Mentor for Nurses. Jane harnesses the power of artificial intelligence (AI) to create a system that personalizes competency development at scale, quickly identifies risk and opportunity, and improves quality outcomes by focusing on critical thinking. Leveraging decades of research and with over 4 million assessments completed, Jane was designed to power lifelong, professional growth of clinical professionals. JaneTM is an important component of HealthStream’s suite of clinical development solutions.

HealthStream Brands